The Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki, or Enhertu from Daiichi Sankyo (DSNKY), in combination with pertuzumab for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer as determined by an FDA-approved test. FDA also approved the PATHWAY anti-HER-2/neu Rabbit Monoclonal Primary Antibody and HER2 Dual ISH DNA Probe Cocktail as companion diagnostic devices for selecting HER2-positive breast cancer patients for treatment with fam-trastuzumab deruxtecan-nxki in combination with pertuzumab.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca’s Latest Study on AZD1613: A Potential Breakthrough for Kidney Disease
- AstraZeneca’s AZD4604: Promising Results in Asthma Treatment Study
- AstraZeneca’s AZD4076: Promising Developments in NASH Treatment
- AstraZeneca’s Acalabrutinib Study: A Potential Game-Changer for CLL Treatment
- AstraZeneca’s AZD4144 Study: A New Hope for Cardiovascular and Kidney Disease?